Vericel Corporation Overview
Pro stress-test →Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. With a market capitalization of roughly $1.97 billion as of November 2025, the company maintains growth through high-margin, autologous cell-therapy products including MACI for cartilage repair and Epicel for severe burns, which drove Q3 2025 total net revenue to a record $67.5 million.
Strategic Profile
Pro stress-test →Vericel operates by turning a patient's own healthy cells into personalized, living therapies to repair damaged tissue, positioning itself as a specialized leader in regenerative medicine with 2025 full-year total revenue guidance projected between $272 million and $276 million. The company demonstrates strong operational fundamentals with a gross margin of 73.5%, a robust cash position of approximately $185 million, and carries absolutely no debt, minimizing financial risk and supporting long-term strategic investments.
Competitive Landscape
Pro stress-test →Vericel operates in a biopharmaceutical industry subject to stringent regulatory oversight with an evolving competitive landscape featuring new entrants and disruptive technologies, requiring navigation of regulatory and competitive pressures to maintain market share. The company differentiates itself within regenerative medicine and advanced biologics through its unique business model targeting both orthopedics and burn care segments with autologous therapies that offer clinical proof and differentiation.
Industry Context
Vericel Corporation operates in Biopharmaceutical / Advanced Cell Therapy / Regenerative Medicine.
Key facts
Founded: 1989 · Headquarters: Cambridge, Massachusetts · Employees: 357-500 · Revenue: $272M-$276M (2025 guidance) · Market cap: $1.97B-$2.1B